The Human Graft-versus-Tumor Response - and How to Exploit It

Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition

Volumn , Issue , 2009, Pages 232-247

  Warren III, Edus H ^a  

^a NONE

Author keywords

Allogeneic HCT; Allogeneic hematopoietic cell transplantation (HCT); B cell contributions to GVT; Classification of mHA encoding genes; Contributions of mHA specific T cell response to GVT; Expression of mHAs in normal tissues and leukemia; Graft versus tumor (GVT); Human genomic diversity and number of mHAs; Molecular characterization of mHAs

Indexed keywords

EID: 78049256035     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303537.ch18     Document Type: Chapter

References (194)

1. Barnes DW, Corp MJ, Loutit JF, Neal FE. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J 1956; 2: 626-7.
2. Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol 1957; 3: 241-52.
3. Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068-73.
4. Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graftversus- host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-33.
5. Odom LF, August CS, Githens JH et al. Remission of relapsed leukaemia during a graft-versushost reaction. A "graft-versus-leukaemia reaction" in man? Lancet 1978; 2: 537-40.
6. Sullivan KM, Shulman HM. Chronic graft-versushost disease, obliterative bronchiolitis, and graftversus- leukemia effect: case histories. Transplant Proc 1989; 21(3 Suppl 1): 51-62.
7. Higano CS, Brixey M, Bryant EM et al. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transplantation 1990; 50: 175-7.
8. Collins RH Jr., Rogers ZR, Bennett M, Kumar V, Nikein A, Fay JW. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versusleukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992; 10: 391-5.
9. deMagalhaes-Silverman M, Donnenberg A, Hammert L et al. Induction of graft-versusleukemia effect in a patient with chronic lymphocytic leukemia. Bone Marrow Transplant 1997; 20: 175-7.
10. van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graftversus- lymphoma effect. Bone Marrow Transplant 1997; 19: 977-82.
11. Libura J, Hoffmann T, Passweg J et al. Graftversus- myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24: 925-7.
12. Moscardo F, Martinez JA, Sanz GF et al. Graftversus- tumour effect in non-small-cell lung cancer after allogeneic peripheral blood stem cell transplantation. Br J Haematol 2000; 111: 708-10.
13. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-5.
14. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-50.
15. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195-204.
16. Collins RH Jr, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-44.
17. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-76.
18. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-6.
19. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-63.
20. Khouri IF, Keating M, Korbling M et al. Transplant- lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-24.
21. Baron F, Maris MB, Sandmaier BM et al. Graftversus- tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003.
22. Martino R, Caballero MD, Simon JA et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243-5.
23. Childs R, Chernoff A, Contentin N et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-8.
24. Hentschke P, Barkholt L, Uzunel M et al. Lowintensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253-61.
25. Bregni M, Dodero A, Peccatori J et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-6.
26. Bregni M, Fleischhauer K, Bernardi M et al. Bone marrow gammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. Bone Marrow Transplant 2006; 37: 311-15.
27. Bishop MR, Fowler DH, Marchigiani D et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886-92.
28. Horowitz MM, Gale RP, Sondel PM et al. Graftversus- leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-62.
29. Gale RP, Horowitz MM, Ash RC et al. Identicaltwin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 646-52.
30. Marmont AM, Horowitz MM, Gale RP et al. Tcell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-30.
31. Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia? Lancet 1984; 2: 28-30.
32. Fefer A, Sullivan KM, Weiden PL et al. Graft versus leukemia effect in man. The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. In: Truitt R, Gale RP, Bortin MM, editors. Cellular Immunotherapy of Cancer. New York: Alan R Liss; 1987. pp. 401-8.
33. Barrett AJ, Ringden O, Zhang MJ et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000; 95: 3323-7.
34. Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561-8.
35. Fefer A, Robinson N, Benyunes MC et al. Interleukin- 2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. Cancer J Sci Am 1997; 3(Suppl 1): S48-53.
36. Fefer A. Interleukin-2 in the treatment of hematologic malignancies. Cancer J Sci Am 2000; 6(Suppl 1): S31-2.
37. Benyunes MC, Massumoto C, York A et al. Interleukin- 2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 1993; 12: 159-63.
38. Benyunes MC, Higuchi C, York A et al. Immunotherapy with interleukin 2 with or without lymphokine- activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplant 1995; 16: 283-8.
39. Fefer A, Einstein AB, Thomas ED et al. Bonemarrow transplantation for hematologic neoplasia in 16 patients with identical twins. N Engl J Med 1974; 290: 1389-93.
40. Fefer A, Buckner CD, Thomas ED et al. Cure of hematologic neoplasia with transplantation of marrow from identical twins. N Engl J Med 1977; 297: 146-8.
41. Hess AD, Thoburn CJ. Immunobiology and immunotherapeutic implications of syngeneic/ autologous graft-versus-host disease. Immunol Rev 1997; 157: 111-23.
42. Giralt S, Weber D, Colome M et al. Phase I trial of cyclosporine-induced autologous graft-versushost disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol 1997; 15: 667-73.
43. Baron F, Gothot A, Salmon JP et al. Clinical course and predictive factors for cyclosporineinduced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation. Br J Haematol 2000; 111: 745-53.
44. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLAmismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-9.
45. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100.
46. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002; 100: 1935-47.
47. Aversa F, Terenzi A, Tabilio A et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005; 23: 3447-54.
48. Leung W, Iyengar R, Turner V et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004; 172: 644-50.
49. Leung W, Iyengar R, Triplett B et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005; 174: 6540-5.
50. Hsu KC, Keever-Taylor CA, Wilton A et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-84.
51. Hsu KC, Gooley T, Malkki M et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12: 828-36.
52. Ruggeri L, Mancusi A, Capanni M et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-40.
53. Michalek J, Collins RH, Hill BJ, Brenchley JM, Douek DC. Identification and monitoring of graft-versus-host specific T-cell clone in stem cell transplantation. Lancet 2003; 361: 1183-5.
54. Thomas E, Storb R, Clift RA et al. Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832-43.
55. Thomas ED, Storb R, Clift RA et al. Bonemarrow transplantation (second of two parts). N Engl J Med 1975; 292: 895-902.
56. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995; 86: 4337-43.
57. Alyea EP, Soiffer RJ, Canning C et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998; 91: 3671-80.
58. Soiffer RJ, Alyea EP, Hochberg E et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002; 8: 625-32.
59. Takami A, Sugimori C, Feng X et al. Expansion and activation of minor histocompatibility antigen HY-specific T cells associated with graft-versusleukemia response. Bone Marrow Transplant 2004; 34: 703-9.
60. Zorn E, Wang KS, Hochberg EP et al. Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res 2002; 8: 2052-60.
61. Kircher B, Stevanovic S, Urbanek M et al. Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion. Br J Haematol 2002; 117: 935-9.
62. Orsini E, Bellucci R, Alyea EP et al. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res 2003; 63: 2561-8.
63. Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003; 100: 2742-7.
64. Kircher B, Wolf M, Stevanovic S et al. Hematopoietic lineage-restricted minor histocompatibility antigen HA-1 in graft-versus-leukemia activity after donor lymphocyte infusion. J Immunother 2004; 27: 156-60.
65. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA et al. Direct cloning of leukemiareactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 2004; 18: 798-808.
66. Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA et al. Minor histocompatibility antigenspecific T cells with multiple distinct specificities can be isolated by direct cloning of IFNgammasecreting T cells from patients with relapsed leukemia responding to donor lymphocyte infusion. Leukemia 2005; 19: 83-90.
67. Cook MA, Milligan DW, Fegan CD et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004; 103: 1521-6.
68. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19: 1446-51.
69. Mackinnon S, Hows JM, Goldman JM. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 1990; 76: 2037-45.
70. Sconocchia G, Lau M, Provenzano M et al. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood 2005; 106: 3666-72.
71. Rotzschke O, Falk K, Wallny HJ, Faath S, Rammensee HG. Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y. Science 1990; 249: 283-7.
72. Wallny HJ, Rammensee HG. Identification of classical minor histocompatibility antigen as cellderived peptide. Nature 1990; 343: 275-8.
73. den Haan JM, Sherman NE, Blokland E et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995; 268: 1476-80.
74. Wang W, Meadows LR, den Haan JM et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269: 1588-90.
75. Shastri N, Cardinaud S, Schwab SR, Serwold T, Kunisawa J. All the peptides that fit: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol Rev 2005; 207: 31-41.
76. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005; 23: 975-1028.
77. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998; 91: 2197-207.
78. Bleakley M, Riddell SR. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004; 4: 371-80.
79. Dolstra H, Fredrix H, Maas F et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med 1999; 189: 301-8.
80. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. J Exp Med 2003; 197: 1279-89.
81. Warren EH, Otterud BE, Linterman RW et al. Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens. Tissue Antigens 2002; 59: 293-303.
82. Akatsuka Y, Nishida T, Kondo E et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med 2003; 197: 1489-500.
83. de Rijke B, van Horssen-Zoetbrood A, Beekman JM et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005; 115: 3506-16.
84. Lahn BT, Page DC. Functional coherence of the human Y chromosome. Science 1997; 278: 675-80.
85. Skaletsky H, Kuroda-Kawaguchi T, Minx PJ et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 2003; 423: 825-37.
86. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-320.
87. Spierings E, Brickner AG, Caldwell JA et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood 2003; 102: 621-9.
88. Brickner AG, Warren EH, Caldwell JA et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. J Exp Med 2001; 193: 195-206.
89. den Haan JM, Meadows LM, Wang W et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science 1998; 279: 1054-7.
90. Terakura S, Murata M, Warren EH et al. A single minor histocompatibility antigen encoded by UGT2B17 and presented by human leukocyte antigen-A*2902 and -B*4403. Transplantation 2007; 83: 1242-8.
91. Wilson W III, Pardo-Manuel de Villena F, Lyn- Cook BD et al. Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 2004; 84: 707-14.
92. Jakobsson J, Ekstrom L, Inotsume N et al. Large differences in testosterone excretion in Korean and Swedish men are strongly associated with a UDP-glucuronosyl transferase 2B17 polymorphism. J Clin Endocrinol Metab 2006; 91: 687-93.
93. Park J, Chen L, Ratnashinge L et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev 2006; 15: 1473-8.
94. McCarroll SA, Hadnott TN, Perry GH et al. Common deletion polymorphisms in the human genome. Nat Genet 2006; 38: 86-92.
95. de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte- defined non-MHC antigens. J Immunol 1992; 149: 1788-94.
96. Dolstra H, Fredrix H, Preijers F et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. J Immunol 1997; 158: 560-5.
97. van der Harst D, Goulmy E, Falkenburg JH et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 1994; 83: 1060-6.
98. Faber LM, van der Hoeven J, Goulmy E et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Clin Invest 1995; 96: 877-83.
99. Faber LM, van Luxemburg-Heijs SA, Veenhof WF, Willemze R, Falkenburg JH. Generation of CD4+ cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: implications for graft-versus-leukemia reactivity. Blood 1995; 86: 2821-8.
100. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A 1999; 96: 8639-44.
101. Lapidot T, Sirard C, Vormoor J et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-8.
102. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
103. Meadows L, Wang W, den Haan JM et al. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that signifi- cantly affects T cell recognition. Immunity 1997; 6: 273-81.
104. Pierce RA, Field ED, Mutis T et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. J Immunol 2001; 167: 3223-30.
105. Tykodi SS, Warren EH, Thompson JA et al. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004; 10: 7799-811.
106. Fujii N, Hiraki A, Ikeda K et al. Expression of minor histocompatibility antigen, HA-1, in solid tumor cells. Transplantation 2002; 73: 1137-41.
107. Klein CA, Wilke M, Pool J et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. J Exp Med 2002; 196: 359-68.
108. Miyazaki M, Akatsuka Y, Nishida T et al. Potential limitations in using minor histocompatibility antigen-specific cytotoxic T cells for targeting solid tumor cells. Clin Immunol 2003; 107: 198-201.
109. Claret EJ, Alyea EP, Orsini E et al. Characterization of T cell repertoire in patients with graftversus- leukemia after donor lymphocyte infusion. J Clin Invest 1997; 100: 855-66.
110. Orsini E, Alyea EP, Schlossman R et al. Changes in T cell receptor repertoire associated with graftversus- tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant 2000; 25: 623-32.
111. Lin MT, Gooley T, Hansen JA et al. Absence of statistically significant correlation between disparity for the minor histocompatibility antigen- HA-1 and outcome after allogeneic hematopoietic cell transplantation. Blood 2001; 98: 3172-3.
112. Akatsuka Y, Warren EH, Gooley TA et al. Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versushost disease after haematopoietic stem cell transplantation from an HLA-identical sibling. Br J Haematol 2003; 123: 671-5.
113. Terakura S, Murata M, Nishida T et al. A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. Br J Haematol 2005; 129: 221-8.
114. Hinds DA, Stuve LL, Nilsen GB et al. Wholegenome patterns of common DNA variation in three human populations. Science 2005; 307: 1072-9.
115. Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet 2006; 38: 75-81.
116. Kruglyak L, Nickerson DA. Variation is the spice of life. Nat Genet 2001; 27: 234-6.
117. Gratwohl A, Hermans J, Niederwieser D, van Biezen A, van Houwelingen HC, Apperley J. Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol J 2001; 2: 363-70.
118. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood 2004; 103: 347-52.
119. Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-23.
120. Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450-7.
121. Molldrem JJ, Clave E, Jiang YZ et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529-34.
122. Yong AS, Rezvani K, Savani BN et al. High PR3 or ELA2 expression by CD34+ cells in advanced phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide driven graft-versus-leukemia effects. Blood 2007; 100: 770-5.
123. Rezvani K, Grube M, Brenchley JM et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102: 2892-900.
124. Rezvani K, Yong AS, Savani BN et al. Graftversus- leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes following allogeneic stem cell transplantation for acute lymphoblastic leukemia (ALL). Blood 2007; 110: 1924-32.
125. Stelljes M, Strothotte R, Pauels HG et al. Graftversus- host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cellmediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets. Blood 2004; 104: 1210-16.
126. van Leeuwen A, Goulmy E, van Rood JJ. Major histocompatibility complex-restricted antibody reactivity mainly, but not exclusively, directed against cells from male donors. J Exp Med 1979; 150: 1075-83.
127. Miklos DB, Kim HT, Zorn E et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 2004; 103: 353-9.
128. Miklos DB, Kim HT, Miller KH et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973-8.
129. Wu CJ, Yang XF, McLaughlin S et al. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest 2000; 106: 705-14.
130. Yang XF, Wu CJ, McLaughlin S et al. CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 2001; 98: 7492-7.
131. Yang XF, Wu CJ, Chen L et al. CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res 2002; 62: 5517-22.
132. Bellucci R, Wu CJ, Chiaretti S et al. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood 2004; 103: 656-63.
133. Bellucci R, Alyea EP, Chiaretti S et al. Graftversus- tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 2005; 105: 3945-50.
134. Jager E, Jager D, Karbach J et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000; 191: 625-30.
135. Jager E, Nagata Y, Gnjatic S et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A 2000; 97: 4760-5.
136. Redon R, Ishikawa S, Fitch KR et al. Global variation in copy number in the human genome. Nature 2006; 444: 444-54.
137. Sharp AJ, Cheng Z, Eichler EE. Structural variation of the human genome. Annu Rev Genomics Hum Genet 2006; 7: 407-42.
138. Levy S, Sutton G, Ng PC et al. The diploid genome sequence of an individual human. PLoS Biol 2007; 5: e254.
139. Sullivan KM, Deeg HJ, Sanders J et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood 1986; 67: 1172-5.
140. Sullivan KM, Storb R, Buckner CD et al. Graftversus- host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320: 828-34.
141. Dawson MA, Spencer A. Successful use of haploidentical stem-cell transplantation with KIR mismatch as initial therapy for poor-risk myelodysplastic syndrome. J Clin Oncol 2005; 23: 4473-4.
142. Davies SM, Ruggieri L, DeFor T et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002; 100: 3825-7.
143. Farag SS, Bacigalupo A, Eapen M et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006; 12: 876-84.
144. Beelen DW, Ottinger HD, Ferencik S et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005; 105: 2594-600.
145. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016-20.
146. Cabrera R, Diaz-Espada F, Barrios Y et al. Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma. Bone Marrow Transplant 2000; 25: 1105-8.
147. Neelapu SS, Munshi NC, Jagannath S et al. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 2005; 36: 315-23.
148. Cathcart K, Pinilla-Ibarz J, Korontsvit T et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037-42.
149. Rusakiewicz S, Molldrem JJ. Immunotherapeutic peptide vaccination with leukemia-associated antigens. Curr Opin Immunol 2006; 18: 599-604.
150. Mailander V, Scheibenbogen C, Thiel E, Letsch A, Blau IW, Keilholz U. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia 2004; 18: 165-6.
151. Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004; 101: 13885-90.
152. Chen X, Regn S, Raffegerst S, Kolb HJ, Roskrow M. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigenpresenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br J Haematol 2000; 111: 596-607.
153. Choudhury BA, Liang JC, Thomas EK et al. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 1999; 93: 780-6.
154. Brouwer RE, van der Hoorn M, Kluin-Nelemans HC, van Zelderen-Bhola S, Willemze R, Falkenburg JH. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Hum Immunol 2000; 61: 565-74.
155. Woiciechowsky A, Regn S, Kolb HJ, Roskrow M. Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 2001; 15: 246-55.
156. Rousseau RF, Biagi E, Dutour A et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 2006; 107: 1332-41.
157. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versusleukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-8.
158. Guglielmi C, Arcese W, Dazzi F et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397-405.
159. Porter DL, Levine BL, Bunin N et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006; 107: 1325-31.
160. Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemiareactive cytotoxic T lymphocytes. Blood 1999; 94: 1201-8.
161. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 1038-44.
162. Warren EH, Gavin MA, Simpson E et al. The human UTY gene encodes a novel HLA-B8- restricted H-Y antigen. J Immunol 2000; 164: 2807-14.
163. Ivanov R, Hol S, Aarts T, Hagenbeek A, Slager EH, Ebeling S. UTY-specific TCR-transfer generates potential graft-versus-leukaemia effector T cells. Br J Haematol 2005; 129: 392-402.
164. Brickner AG, Evans AM, Mito JK et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood 2006; 107: 3779-86.
165. Slager EH, Honders MW, van der Meijden ED et al. Identification of the angiogenic endothelialcell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006; 107: 4954-60.
166. de Rijke B, van Horssen-Zoetbrood A, Beekman JM et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest 2005; 115: 3506-16.
167. Kawase T, Akatsuka Y, Torikai H et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood 2007; 110: 1055-63.
168. Bocchia M, Korontsvit T, Xu Q et al. Specific human cellular immunity to bcr-abl oncogenederived peptides. Blood 1996; 87: 3587-92.
169. Dermime S, Bertazzoli C, Marchesi E et al. Lack of T-cell-mediated recognition of the fusion region of the pml/RAR-alpha hybrid protein by lymphocytes of acute promyelocytic leukemia patients. Clin Cancer Res 1996; 2: 593-600.
170. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992; 327: 1209-15.
171. Scholl S, Salzmann S, Kaufmann AM, Hoffken K. Flt3-ITD mutations can generate leukaemia specific neoepitopes: potential role for immunotherapeutic approaches. Leuk Lymphoma 2006; 47: 307-12.
172. Graf C, Heidel F, Tenzer S et al. A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells. Blood 2007; 109: 2985-8.
173. Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-74.
174. Mullighan CG, Goorha S, Radtke I et al. Genomewide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-64.
175. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286-93.
176. Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51: 99-107.
177. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003; 423: 255-60.
178. Park IK, Qian D, Kiel M et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423: 302-5.
179. Steele JC, Torr EE, Noakes KL et al. The polycomb group proteins, BMI-1 and EZH2, are tumour-associated antigens. Br J Cancer 2006; 95: 1202-11.
180. Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006; 354: 1166-76.
181. Edinger M, Hoffmann P, Ermann J et al. CD4+CD25+ regulatory T cells preserve graftversus- tumor activity while inhibiting graftversus- host disease after bone marrow transplantation. Nat Med 2003; 9: 1144-50.
182. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-24.
183. Ciceri F, Bonini C, Marktel S et al. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 2007; 109: 4698-707.
184. Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 2006; 107: 2294-302.
185. Riddell SR, Elliott M, Lewinsohn DA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996; 2: 216-23.
186. Traversari C, Marktel S, Magnani Z et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 2007; 109: 4708-15.
187. Clackson T, Yang W, Rozamus LW et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A 1998; 95: 10437-42.
188. Straathof KC, Spencer DM, Sutton RE, Rooney CM. Suicide genes as safety switches in T lymphocytes. Cytotherapy 2003; 5: 227-30.
189. Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric receptor genes in human T cells. J Immunol Methods 2001; 248: 67-76.
190. Cooper LJ, Topp MS, Serrano LM et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-Blineage leukemia effect. Blood 2003; 101: 1637-44.
191. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-9.
192. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466-76.
193. Evans LS, Witte PR, Feldhaus AL et al. Expression of chimeric granulocyte-macrophage colonystimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth. Hum Gene Ther 1999; 10: 1941-51.
194. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 1355-62.